Table 3 Baseline characteristics of the paired longitudinal study

From: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy

 

No-Statin-No-PCSK9 inhibitor therapy (n = 10)

Statin monotherapy (n = 15)

Add-on PCSK9 inhibitor therapy (n = 16)

P value

Mean age (yr)

65.3 ± 8.6

65.3 ± 8.6

66.1 ± 9.1

0.9887

Male sex (%)

50

53

50

0.9846

BMI (kg/m2)

24.8 ± 2.5

23.8 ± 2.6

24.7 ± 3.9

0.9847

Smoking (%)

0

7

0

0.9400

Past history of coronary heart disease (%)

60

67

63

0.9586

Family history of coronary heart disease (%)

30

27

38

0.8705

Heterozygous familial hypercholesterolemia (%)

20

80

81

0.0170

  1. Data were average ± standard deviation. The p-value was determined by using Kruskal–Wallis test
Back to article page